Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells (MPCs) Therapy for Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The subject is between 18-70 years of age, regardless of gender~2. The subject has a Kellgren-Lawrence grading, as determined by American College of Rheumatology (ACR) criteria for osteoarthritis of the knee, below grade 4~3. The subject or the subject's legally acceptable representative must be willing to participate in the trial, to receive cell therapy and to provide signed and dated informed consent forms~Exclusion Criteria:~1. The subject has an allergic history or is of an allergic constitution~2. The subject has uncontrolled or hard-to-control diseases of heart, liver, kidney or lung~3. The subject has uncontrolled or hard-to-control diseases of cardiovascular or endocrine system~4. The subject has severe infectious diseases or a malignant tumour~5. The subject has coagulation disorders~6. The subject has a BMI of over 30~7. The subject has used traditional Chinese medicine containing anti-inflammatory agents in the 2 weeks preceding the trial~8. The subject has received other intra-articular injections in the 2 months preceding the trial~9. The subject has complications or diseases of: systemic or rheumatoid arthritis, Chondrocalcinosis articular， Hemochromatosis，inflammatory arthropathy，avascular necrosis of femoral head，Paget's disease，hemophilic arthropathy，infectional arthritis，Charcot's disease，villonodular synovitis or synovial chondromatosis~10. The subject tests positive for: HIV, hepatitis virus, syphilis or other infectious diseases~11. The subject has a history of alcoholism, drug abuse, or mental illness~12. The subject has participated in any other clinical trial in the 3 months prior to this trial~13. The subject is pregnant, lactating or is planning to conceive within the next 6 months~14. The subject has any other unsuitable or adverse condition to be determined by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Mesenchymal progenitor cells (Type: EXPERIMENTAL): Administrated for intra-articular use of Mesenchymal progenitor cells
- Sodium Hyaluronate (Type: ACTIVE_COMPARATOR): Administrated for intra-articular use of Sodium Hyaluronate.

Based on this trial design, predict the completion outcome and termination type (if applicable).